Multifunctional chitosan-coated poly(lactic-co-glycolic acid) nanoparticles for spatiotemporally controlled codelivery of ceramide and C-phycocyanin to treat atopic dermatitis

Abstract

Atopic dermatitis is an inflammatory disease associated with defective skin barrier. The co-administration of a lipid-enhancing skin barrier composed of ceramide with an anti-inflammatory agent is required to effectively treat atopic dermatitis. As atopic dermatitis treatment is affected by the dosage and frequency of medication, the development of nanoparticles that have long-term efficacy with a single dose would be advantageous. In this study, skin-sensitive chitosan nanoparticles codelivering ceramide and C-phycocyanin were developed to provide anti-inflammatory effects with no cytotoxicity, and their effect on stratum corneum formation in a rat atopic dermatitis model was examined. Analysis of the messenger RNA expression of keratinization factors demonstrated that the stratum corneum–formation effect of poly(lactic-co-glycolic acid) nanoparticles containing ceramide was similar to or higher than that of ceramide alone. Compared to the nanoparticles without C-phycocyanin, nanoparticles coated with C-phycocyanin and chitosan attenuated histamine release. In addition, despite frequent washing, the nanoparticles were well fixed to the epidermis after their administration. The results suggest that a single treatment with the combination of lipid therapy/anti-inflammatory nanoparticles is a convenient and high-efficiency means to increase stratum corneum formation in atopic dermatitis patients.

Keywords

Poly(lactic-co-glycolic acid)nanoparticle ceramide C-phycocyanin atopic dermatitis controlled release

Get full access to this article

View all access options for this article.

References

Boguniewicz

Leung

DY.

Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011; 242(1): 233–246.

Lee

SH.

Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy Asthma Immunol Res 2014; 6(4): 276–287.

Imokawa

Abe

Jin

et al . Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol 1991; 96(4): 523–526.

Coderch

López

Maza

et al . Ceramides and skin function. Am J Clin Dermatol 2003; 4(2): 107–129.

Simpson

Böhling

Bielfeldt

et al . Improvement of skin barrier function in atopic dermatitis patients with a new moisturizer containing a ceramide precursor. J Dermatolog Treat 2012; 24(2): 122–125.

Wahlgren

CF.

Itch and atopic dermatitis: an overview. J Dermatol 1999; 26(11): 770–779.

Wilson

The

Batia

et al . The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 2013; 155(2): 285–295.

Lee

Jeong

Lee

SH.

Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis. Yonsei Med J 2010; 51(6): 808–822.

Voegeli

Rawlings

Breternitz

et al . Increased stratum corneum serine protease activity in acute eczematous atopic skin. Brit J Dermatol 2009; 161(1): 70–77.

10.

Furue

Terao

Rikihisa

et al . Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Brit J Dermat 2003; 148(1): 128–133.

11.

Arellano

Wentworth

Arana

et al . Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127(4): 808–816.

12.

Han

Park

Jang

et al . A natural dye, Niram improves atopic dermatitis through down-regulation of TSLP. Environ Toxicol Pharmacol 2014; 38(3): 982–990.

13.

Roumestan

Henriquet

Gougat

et al . Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms. Clin Exp Allergy 2008; 38(6): 947–956.

14.

Sivaranjani

Rao

Rajeev

Role of reactive oxygen species and antioxidants in atopic dermatitis. J Clin Diagn Res 2013; 7(12): 2683–2685.

15.

Romay

Ledon

Gonzalez

Effects of phycocyanin extract on prostaglandin E2 levels in mouse ear inflammation test. Arzneimittelforsch 2000; 50(12): 1106–1109.

16.

Romay

Armesto

Remirez

et al . Antioxidant and anti-inflammatory properties of C-phycocyanin from blue-green algae. Inflamm Res 1998; 47(1): 36–41.

17.

Remirez

Ledon

Gonzalez

Role of histamine in the inhibitory effects of phycocyanin in experimental models of allergic inflammatory response. Mediat Inflamm 2002; 11(2): 81–85.

18.

Rol

Llanos

Arias

et al . Interferon-alpha and c-phycocyanin for the treatment of autoimmune diseases, allergic diseases and cancer. Patent EP1955706A1, USA, 2009.

19.

Cingi

Conk-Dalay

Cakli

et al . The effects of spirulina on allergic rhinitis. Eur Arch Otorhinolaryngol 2008; 265(10): 1219–1223.

20.

Leung

DYM

Boguniewicz

Howell

et al . New insights into atopic dermatitis. J Clin Invest 2004; 113(5): 651.

21.

Simpson

EL.

Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin 2010; 26(3): 633–640.

22.

Lipka

Semmeler-Behnke

Sperling

et al . Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials 2010; 31(25): 6574–6581.

23.

des Rieux

Fievez

Garinot

et al . Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006; 116(1): 1–27.

24.

Bathe

Kapoor

Transdermal drug delivery system: formulation development evaluation-an overview. Int J Adv Res 2015; 6(1): 7.

25.

Danhier

Ansorena

Silva

et al . PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012; 161(2): 505–522.

26.

Makadia

Siegel

SJ.

Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymer 2011; 3(3): 1377–1397.

27.

Kumari

Yadav

SC.

Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010; 75(1): 1–18.

28.

Soppimath

Aminabhavi

Kulkarni

et al . Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001; 70(1): 1–20.

29.

Sarmento

Mazzaglia

Bonferoni

et al . Effect of chitosan coating in overcoming the phagocytosis of insulin loaded solid lipid nanoparticles by mononuclear phagocyte system. Carbohydr Polym 2011; 84(3): 919–925.

30.

Agnihotri

Mallikarjuna

Aminabhavi

et al . Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release 2004; 100(1): 5–28.

31.

Singla

Chawla

Chitosan: some pharmaceutical and biological aspects-an update. J Pharm Pharmacol 2001; 53(8): 1047–1067.

32.

Husain

Al-Samadani

Najeeb

et al . Chitosan biomaterials for current and potential dental applications. Materials 2017; 10(6): 602.

33.

Jung

Yoon

Lee

et al . Thermodynamic insights and conceptual design of skin-sensitive Chitosan Coated Ceramide/PLGA Nanodrug for regeneration of stratum corneum on atopic dermatitis. Sci Rep 2015; 5: 18089.

34.

Jain

RA.

The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide)(PLGA) devices. Biomaterials 2000; 21(23): 2475–2490.

35.

Knor

Meholjic-Fetahobic

Mehmedagic

Stratum corneum hydration and skin surface pH in patients with atopic dermatitis. Acta Dermatovenerol Croat 2011; 19(4): 242–247.

36.

Thomsen

SF.

Atopic dermatitis: natural history, diagnosis, and treatment. Int Sch Res Notices 2014; 2014: 1–7.

37.

Coondoo

Phiske

Verma

et al . Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J 2014; 5(4): 416–425.

38.

Astete

Sabliov

CM.

Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed 2006; 17(3): 247–289.

39.

Lertsutthiwong

Noomun

Khunthon

et al . Influence of chitosan characteristics on the properties of biopolymeric chitosan-montmorillonite. Prog Nat Sci Mater 2012; 22(5): 502–508.

40.

Takeda

Mitsutake

Tsuji

et al . Apoptosis occurs via the ceramide recycling pathway in human HaCaT keratinocytes. J Biochem 2006; 139(2): 255–262.

41.

Amin

The role of mast cells in allergic inflammation. Respir Med 2012; 106(1): 9–14.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.15 MB